Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
25%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
4
31%
Ph phase_3
1
8%
Ph phase_4
5
38%
Ph not_applicable
2
15%

Phase Distribution

4

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
5(41.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(12)
Terminated(1)

Detailed Status

Completed12
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (33.3%)
Phase 31 (8.3%)
Phase 45 (41.7%)
N/A2 (16.7%)

Trials by Status

completed1292%
terminated18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Clinical Trial of PCV24 in Adults Aged ≥18 Years

NCT07543198
completedphase_1

Clinical Trial of PCV24 in Adults

NCT06474377
completednot_applicable

Perturbing of HIV Reservoir With Immune Stimulation

NCT02707692
terminatedphase_4

Antibody Production in Immune Disorders

NCT00023504
completednot_applicable

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

NCT01307449
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07543198Phase 1

Clinical Trial of PCV24 in Adults Aged ≥18 Years

Completed
NCT06474377Phase 1

Clinical Trial of PCV24 in Adults

Completed
NCT02707692Not Applicable

Perturbing of HIV Reservoir With Immune Stimulation

Completed
NCT00023504Phase 4

Antibody Production in Immune Disorders

Terminated
NCT01307449Not Applicable

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Completed
NCT03460730Phase 1

Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)

Completed
NCT01781871Phase 4

Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients

Completed
NCT00304382Phase 4

Humoral Determinants of Immunity to Pneumococcal Infection

Completed
NCT01892618Phase 3

Pneumococcal Vaccine in Untreated CLL Patients

Completed
NCT01947010Phase 4

Pneumococcal Vaccination of Crohn Patients

Completed
NCT00137605Phase 1

Early Versus Delayed Pneumococcal Vaccination in HIV

Completed
NCT00836641Phase 4

Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics

Completed
NCT00611611

BLYS and IFN in SLE

Completed

All 13 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
13